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a b s t r a c t
Understanding the mechanisms of drug action has been the primary focus for pharmacological
researchers, traditionally using rodent models. However, non-sentient model systems are now increas-
ingly being used as an alternative approach to better understand drug action or targets. One of these
model systems, the social amoeba Dictyostelium, enables the rapid ablation or over-expression of genes,
and the subsequent use of isogenic cell culture for the analysis of cell signalling pathways in pharmaco-ithium
AP kinase
harmacology
hosphoinositol
alproic acid
logical research. The model also supports an increasingly important ethical view of research, involving
the reduction, replacement and reﬁnement of animals in biomedical research. This review outlines the
use of Dictyostelium in understanding the pharmacological action of two commonly used bipolar disor-
der treatments (valproic acid and lithium). Both of these compounds regulate mitogen activated protein
(MAP) kinase and inositol phospholipid-based signalling by unknown means. Analysis of the molecular
pathways targeted by these drugs in Dictyostelium and translation of discoveries to animal systems has
helped to further understand the molecular mechanisms of these bipolar disorder treatments.
© 2010 Elsevier Ltd. 
ontents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
2. Bipolar disorder background. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
3. Dictyostelium as a model for pharmacology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
4. A summary of valproic acid’s molecular mechanisms of action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
5. A summary of lithium’s molecular mechanisms of action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
6. MAP Kinase and bipolar disorder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Open access under CC BY license.7. Inositol and phosphoinositol attenuation and bipolar disorder. . . . . . . . . . .
8. Conclusion/summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: DAG,diacylglycerol;GSK3/A,mammalian/Dictyosteliumglycogen
ynthase kinase 3/A; IMPase, inositol monophophatase; IPPase, Inositol polyphos-
hate phosphatase; InsP3, inositol 1,4,5-triphosphate; 2M2P, 2-methyl-2-pentenoic
cid; PI, phosphatidylinositol; PIP2, phosphatidylinositol 4,5-biphosphate; PI3K,
hosphatidylinositol 3-kinase; PIP, phosphatidylinositol monophosphate; PO, pro-
yl oligopeptidase; MAPK, mitogen activated protein kinase; MEK, MAPK kinase;
EKK, MEK kinase; MKP, MAP kinase phosphatase; PKA, protein kinase A; PLC,
hospholipaseC;REMI, restriction enzymemediated integration;VPA, valproic acid.
∗ Corresponding author. Tel.: +44 01784 276162; fax: +44 01784 414224.
E-mail address: robin.williams@rhul.ac.uk (R.S.B. Williams).
084-9521© 2010 Elsevier Ltd. 
oi:10.1016/j.semcdb.2010.11.002
Open access under CC BY license.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
1. Introduction
Bipolar disorder, aneurological condition that causes cyclic vari-
ation inmood, gives rise to a devastating effect on quality of life and
signiﬁcantly increases the chance of suicide [1]. To improvediagno-
sis and treatment of bipolar disorder, ongoing research has focused
on identifying the molecular basis of the condition. Research mod-
els used for this purpose have traditionally been rodents. However,
the increasing use of other simple model systems such as the
social amoeba, Dictyostelium discoideum, provides distinct advan-
tages. The following review will introduce bipolar disorder and
Dictyostelium as a biomedical model. The reviewwill then focus on
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wo of themost widely used bipolar disorder treatments – valproic
cid (VPA) and lithium – by ﬁrstly outlining current knowledge
f cell signalling pathways regulated by each treatment, and then
llustrating the use of Dictyostelium (and subsequent translation
o mammalian systems) to enhance our understanding of putative
ipolar disorder-dependent cell signalling changes in both path-
ays.
. Bipolar disorder background
Bipolar disorder (also known as manic depression) is a neuro-
ogical condition giving rise to cyclic and extreme changes inmood.
he two most widely occurring types of bipolar disorder are char-
cterised by slightly different re-occurring states: type 1 describes
ecurrent mood swings from depression to mania, whilst type 2
escribes recurrent mood swings from depression to euthymic
stabilised mood) behaviour or mild forms of mania [2–4]. Bipolar
isorder is amongst the most common serious neurological disor-
ers, with estimates of its worldwide occurrence of up to 4% [4–6].
n equal number of men and women develop this illness, and its
requency is highest in people from a low economic bracket or in
ffspring of those in higher socio-economic indices [7]. In the UK
he ﬁnancial burden on the health system amounts to £4.6 billion
nnually [8] and although it does not in itself cause physical bod-
ly damage, it gives rise to emotionally damaging behaviour and
ears a 15% risk of suicide when left untreated [9]. A recent US
tudy suggests that bipolar disorder occurrence doubled in adults
nd increased by 40-fold for those under 20 year olds from 1994 to
003 [10]. Many studies suggest an heritable risk, since monozy-
otic twins indicate a 60% co-inheritancewhich decreases to 7% for
rst-degree relatives [11].
Current treatments for bipolar disorder include lithium,
nticonvulsant drugs (carbamazepine, Tegretol), valproic acid
Depakote), gabapentin (Neurontin) and lamotrigine (Lamictal),
ntidepressants such as bupropion (Wellbutrin) or sertraline
Zoloft), neuroleptics (e.g. haloperidol) and benzodiazepines (e.g.
orazepam). These treatments require continuous long-term use
nd are thus non-curative. A decision on which treatment to use
s normally based on individual symptoms. Poor response rates
o drug treatment (only marginally better than placebo) occur in
pproximately 35–50% of patients, with signiﬁcant side effects that
ften lead to non-adherence [12].
Research into bipolar disorder remains a hugely complexunder-
aking. This is primarily since there are nowell acceptedmodels for
he condition [13], patients cannot be taken off treatment since this
ay give rise to damaging mood changes, and since the molecular
echanism of bipolar disorder drugs have not been discovered. For
hese reasons current treatments have been found as a secondary
ffect whilst treating other conditions (e.g. epilepsy). However,
hree broad approaches continue to be used in bipolar disorder
esearch: genetics, physiology and pharmacology.
Genetics: Identifying the genetic basis of bipolar disorder is likely
to provide the ultimate origin of the condition and is thus a fun-
damentally important approach. There is clear evidence that the
occurrence of bipolar disorder has a strong genetic component
[14] and a range of speciﬁc loci have been associated with the
disorder [15,16]. However, as a consequence of the large number
of loci involved, this approach is highly complex.
Biochemistry:Understandingphysical changes in individualswith
bipolar disordermay provide an avenue to identify themolecular
basis of the condition. For example, recent studies have shown
bipolar disorder-dependent changes in brain volume [17,18]
brain imaging studies [19], in gene expression [20], enzymatic
activity [21] and in the regulation of cellular components such as
fatty acids [22,23].velopmental Biology 22 (2011) 105–113
• Pharmacology: The identiﬁcation and characterisation of changes
in cell signalling caused by bipolar disorder treatments may
both identify the molecular mechanism causing bipolar disor-
der, and enable the development of more efﬁcacious treatments
or treatments with reduced side effects. The vast array of
genetic risk factors associated with bipolar disorder occurrence
is expected to give rise to changes in only a limited number of sig-
nalling pathways that are then controlled by a small number of
current bipolar disorder treatments. Thus understanding bipolar
disorder-associated signalling pathways may help the treatment
of patients with a wide array of causative factors. However, this
approach is also complex since bipolar disorder treatments have
numerous effects and/or targets, and the primary sites of action
are often unknown. The majority of research into the molecular
basis of bipolar disorder treatments has centred on valproic acid
(VPA) and lithium.
3. Dictyostelium as a model for pharmacology
The use of invertebrate, non-sentient model organisms can
facilitate our understanding of the mechanism of drug action
on cellular level whilst reducing the use of animals in research.
Dictyostelium discoideum is one of these models listed as one
of ten non-mammalian biomedical models recognised by the
US National Institutes of Health (NIH). Dictyostelium is more
complex than other models listed such as Sacchromycies cere-
visiae (baker’s yeast), Schizosaccharomyces pombe (ﬁssion yeast)
or Neurospora crassa (ﬁlamentous fungus) since Dictyostelium cells
undergo chemotactic and randommovement. It also has rudimen-
tary development mechanisms and related signalling pathways.
On the other hand, Dictyostelium is simpler than other models
listed such as Caenorhabditis elegans (round worm) and Drosophila
melanogaster (fruit ﬂy), Danio rerio (zebraﬁsh), and Xenopus trop-
icalis (frog) since it lacks the much more complex developmental
processes involved in the formation of these animals and lacks their
basic neurological networks. Dictyostelium has evolved a strong
niche for studies into cell movement and development [24–26],
for understanding the cellular role of a range of proteins [27], for
evolutionary biology [28] and for a growing range of biomedical
research areas outlined in this edition.
Dictyostelium can be cultured by either growth in nutrient rich
media (ingesting media via macropinocytosis) or in association
with bacteria as a food source (ingesting bacterial cells via endo-
cytosis), and will continue to divide by binary ﬁssion until food or
nutrients are depleted. Thus, in the presence of sufﬁcient nutri-
ents, large quantities of isogenic cells can be cultured and used
for biochemical or cell signalling studies (Fig. 1). Dictyostelium also
has an unusual part of its life cycle, whereby starvation initiates a
development cycle and a range of genes are transcribed enabling
chemically-directed cell movement (chemotaxis) and aggregation
of∼100 000 cells to a single point, followed by a primitive develop-
mental process leading to the formation of distinct cell types (spore
and stalk cells) in a mature fruiting body (Fig. 1). This development
process takes around 24h.
The haploid genome of this Dictyostelium has been fully
sequenced [29] and contains 34MbofDNAwhich is 84-fold smaller
than the human genome, but encodes 12,500 genes. Many of
these genes now contain considerable annotation by the online
research resources [Dictybase.org [30]]. Unusual aspects of the
Dictyostelium genome include a high AT/GC ratio (86:14) and an
average open reading frame of 1756bp with 1.9 introns per gene.
Thus, Dictyostelium provides a simple model system that is well-
characterised at a genetic level.
The use of Dictyostelium as a pharmacological and pharmacoge-
neticmolecularmodel for VPA and lithiumwas initially based upon
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Fig. 1. Dictyostelium as a simplemodel formolecular pharmacology research. Under
control growth conditions; (1) Dictyostelium cells multiply by binary ﬁssion either
in liquid media or in association with bacteria as a food source, until resources are
depleted. (2) Induction of starvation causes cells to stop diving and enter a devel-
opmental phase, whereby expression of a range of developmental genes enables
cells to move together in a process called chemotaxis (where cells move towards
cyclic AMP). (3) Following aggregation of cells, Dictyostelium undergoes develop-
mental differentiation to form a multi-cellular fruiting body, of around 1mm in
height, consisting primarily of spore and stalk cells. The development of molecu-
lar cell biology techniques for Dictyostelium research has enabled this model to be
used inmolecular pharmacology studies using either: (4a) Cell lines containing sin-
gle or multiple ablated (or over-expressed) genes (green); or (4b) Pools of random
insertional mutants (prepared using REMI; yellow) to provide mutant libraries for
drug resistance screens. (5) The cellular role of pharmacological treatments (such
as VPA and lithium (Li+)) can be analysed using either wild type cells, or cell lines
containing ablated or over-expressed genes. (6) Analysis of resistance to the devel-
opmental block by VPA/Li+ can also help to understand and characterise the role
o
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(GSK3) [67,68], the activation of theMAPK signalling pathway [69],f speciﬁc genes or identify novel genes involved in the action of bipolar disorder
reatments. (For interpretation of the references to color in this ﬁgure legend, the
eader is referred to the web version of the article.)
he observation that bothdrugs blockdevelopment, thus enabling a
angeof studies tounderstand theirmechanism(s) of action (Fig. 1):
REMI mutagenesis (Restriction Enzyme Mediated Insertional
mutagenesis [31–33] provides an approach to create a library
of insertional mutants, whereby a selectable marker is randomly
integrated throughout the genome. The resulting pool ofmutants
can then be screened for resistance to VPA or lithium. Mutants
with resistance to the block in development will identify the loci
that control VPA or lithium action [34].
Speciﬁc genes can be deleted within the haploid genome, and
clonal cell lines can be isolated and used for biochemical or
developmental resistance studies. The recent adaption of Cre-
Lox based excision technology in Dictyostelium now enables the
sequential repetition of this process, and thus the targeted abla-
tion of multiple genes in a single cell line [35]. For example, Kay
and co-workers recently ablated six genes in a single cell line [36].elopmental Biology 22 (2011) 105–113 107
• Over-expression of genes, or the expression of ﬂuorescently
tagged genes can be readily carried out [37], and isogenic cell
lines can be isolated and used for studies examining the effect of
VPA and lithium on cell signalling or development.
ThusDictyostelium’suniquebiology allows a rangeof pharmaco-
logical studies to explore the role of VPA and lithium in regulating
cell signalling and multi-cellular development.
4. A summary of valproic acid’s molecular mechanisms of
action
Valproic acid is a simple branched, short chain fatty acid
(2-propylpentanoic acid), that was accidently discovered to func-
tion in seizure control in the early 1960s [38]. Since then its role
has expanded to include its application as amainstay treatment for
bipolar disorder [39,40] and as a widely used prophylactic treat-
ment for migraine [41]. More recently, it has also been proposed
as a new treatment for a variety of conditions including ischemia
[42], cancer [43], Alzheimer’s disease [44], latent HIV [45], in ter-
minal blood loss [46] and traumatic brain injury [47]. In addition to
the beneﬁcial effects of VPA, it also has a number of signiﬁcant side
effects. These include teratogenicity [48],whereby unborn children
have a signiﬁcantly increased chance of birth defects if the drug is
taken by the mother during the ﬁrst trimester of pregnancy [49],
hepatotoxicity [50] and a range of common adverse side effects
including weight gain, tremor, alopecia [51].
Not surprisingly, this gamut of therapeutic roles for VPA has
been associatedwith a variety of cellular mechanisms. These range
from increasing gamma aminobutaric (GABA) levels [41], reduc-
ing de novo inositol synthesis [52,53] and inositol trisphosphate
depletion (InsP3) [54,59,99], to reducing ionchannel activity [55], in
regulation of fatty acid signalling and turnover [56] and in the acti-
vation of themitogen activated protein (MAP) kinase pathway [57].
A role for VPA in GSK3 signalling has also been proposed, initially
through direct inhibition [58], although this could not be repro-
duced by other groups [59,60]. Subsequent experiments showed
contrasting results for an indirect effect of VPA on GSK3, primar-
ily by elevated soluble -catenin levels following treatment [61].
Histone deacetylase inhibition [60] has also been shown to provide
a mechanism of action for VPA—an effect linked to teratogenicity
[62].
5. A summary of lithium’s molecular mechanisms of action
The mechanism of action for lithium has been of consider-
able interest since its re-discovery as a bipolar disorder treatment
by Cade [63]. Lithium is the most commonly used treatment for
bipolardisorder, and it is alsoeffective in reducingpathologicalpro-
cesses in a variety of Alzheimer’s disease models [64]. Side effects
include mild tremor, nausea, diarrhoea and its therapeutic win-
dow is narrow thus requiring regular monitoring of lithium blood
concentration [65]. Furthermore, lithium has been proposed to be
a teratogen since administration during pregnancy also increases
the risk of congenital heart defects [66].
Despite the simple nature of thismolecule (the third element on
the periodic table), it still remains unclear how lithium functions in
its therapeutic action. However, it has been widely shown to reg-
ulate four signalling pathways potentially associated with bipolar
disorder: the inhibition of the enzyme glycogen synthase kinasethe attenuation of inositol signalling [54] and more recently phos-
phoinositol signalling [70].
A pharmacological approach to understand how VPA and
lithium regulate cell signalling therefore requires the understand-
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ng of how these various pathways are modulated, and what genes
nd pathways are responsible for these drug effects. Here we will
ocus on the regulation of theMAP Kinase pathway and the inositol
nd phosphoinositol-dependent pathways.
. MAP Kinase and bipolar disorder
Bipolar disorder has been associated with changes in neu-
otrophic signalling cascades, neuronal cellular atrophy and
egional reductions in brain volume [71,72]. Structural imaging
tudies of patients with bipolar disorder have demonstrated
educed greymatter volumes in areas of the orbital andmedial pre-
rontal cortex, ventral striatum and hippocampus and enlargement
f third ventricles relative to healthy control patients [73,74]. This
ffect has also been shown in postmortemneuropathological stud-
es with reductions in cortex volume [74], glial cell counts [75] and
euron size in various regions of the prefrontal cortex and amyg-
ala of bipolar disorder patients [73]. Glial cell reductions in these
egions are particularly interesting due to the role of these cells
n regulating the development and maintenance of synaptic net-
orks. Changes in neurotrophic signalling and atrophy may thus
rovide the mechanism of bipolar disorder pathology.
Lithium and VPA treatment have been shown to reverse or
ttenuate brain structural changes found in bipolar disorder
76,77], suggesting this neuroprotective effect to be the key mech-
nism of bipolar disorder treatment. The effect is thought to occur
hrough the MAPK pathway by increasing the activation (phos-
horylation) of the extracellular signal-regulated kinase 2 (ERK2).
ncreased phosphorylation of ERK2 (pERK2) in response to treat-
ent is seen in culturedneuronal cells, rathippocampusand frontal
ortex and cultured rat thyroid cells [78–80]. As theMAPKpathway
as been shown tomodulate processes such as neuronal differenti-
tion, neuronal survival and long term neuroplasticity it is likely to
e involved in protecting against bipolar disorder-dependent neu-
onal death and is thus increasingly seen as the potential origin of
he disorder [81]. Elucidating howVPA and lithium cause this effect
s therefore of great therapeutic interest in understanding bipolar
isorder aetiology [80,82].
Employing Dictyostelium has shown that both VPA and lithium
lso up-regulate the activation of the MAPK pathway [82] by
ncreasing pERK2 levels in this simple biomedical model system
Fig. 2A and B). In the case of VPA, this effect was shown to occur
apidly (within 10min)—suggesting a biochemical basis for drug
ction rather than genetic regulation. Themechanismof actionwas
uggested to be independent of upstream regulation, since it was
ot dependent on receptor phosphorylation (the cAMP receptor
; cAR1) and to be independent of G protein dissociation (using
RET analysis or genetic deletion of G protein signalling). Further-
ore increasedpERK2 levels could not be phenocopied by reducing
IP3 production (using awidely-employed inhibitor to PI3K-family
roteins, LY294002). However, a range of experiments suggested
hat VPA may function through blocking de-phosphorylation of
ERK2 (Fig. 2). These experiments showed that pERK2 level upreg-
lation is phenocopied by a reduced cAMP production (through
blation of adenylate cyclase A); pharmacological inhibition of
rotein kinase A (PKA) activity and pharmacological inhibition of
hosphotyrosine phosphatase activity (by vanadate)—all implicat-
ng de-phosphorylation of pERK2 as the mechanism of action for
PA. The interaction of MAPK and cAMP/PKA pathway is com-
lex [83] with multiple points of interaction and cross-regulation.
urther analysis of this crossover in both Dictyostelium and mam-
alian systems will be necessary to better deﬁne the mechanism
f VPA action on this pathway. The results also strongly implicate
SK3/A inhibition in reducing extended pERK2 levels, since both
ithium and a speciﬁc GSK3/A inhibitor cause increased pERK2 lev-velopmental Biology 22 (2011) 105–113
els at three and four minutes post stimulation [82], as does genetic
ablation of GSKA in isogenic cell lines (Fig. 2C). This work also sug-
gests that the lithium-induced pERK2 up-regulation is likely to be
caused through direct inhibition of GSK3/A activity, leading to a
decrease in PKA/MKP activity. This reasoning is also supported by
the observation that ablation of GSK3/A blocks lithium-catalysed
extended pathway activation at four minutes post stimulation
(Fig. 2A,and C). These results suggest that VPA increases acti-
vated MAPK levels through inhibition of a cAMP/PKA dependent
de-phosphorylation of pERK2 whilst the lithium-dependent effect
occurs through GSKA/3-dependent signalling.
One important aspect of VPA pharmacology is the use of com-
pounds related to VPA to distinguish between different targets in
cell signalling. These studies were initially based upon the iden-
tiﬁcation of reactive metabolites of VPA. For example -oxidation
of VPA gives rise to the metabolite E-2-propylpent-2-enoic acid
whereas the action of the enzyme P450 results in the formation
of 3-propylpent-4-enoic acid. These compounds show different
inhibitory activity towards -oxidation [84]. Furthermore, the ter-
atogenic effect of VPA is also highly structurally dependent [62],
requiring a carboxylic acid head group, a branch point on the sec-
ond carbon, a hydrogen on the second carbon, and enantiomeric
speciﬁcity (S-enantiomers show greater teratogenicity than R-
enantiomers).
In Dictyostelium we have employed a range of VPA-related
compounds to investigate the structural requirements for pERK2
up-regulation, and used this to differentiate this effect from other
VPA sensitive pathways, mechanisms of action and therapeutic
effects. For example, the amide derivative of VPA (valpromide)
shows improved efﬁcacy in seizure control [85] and lacks ter-
atogenicity but shows only intermediate up-regulation of pERK2
levels in Dictyostelium (Fig. 2D). The elevation of pERK2 is also
enantiomer speciﬁc since S-2-pentyl-4-pentynoic acid is strongly
activating compared to its enantiomer R-2-pentyl-4-pentynoic
acid that shows little effect (Fig. 2D). Interestingly, these two
enantiomers have been shown to improve learning and mem-
ory with the more teratogenic S enantiomer exhibiting a stronger
potency [86], however this increase was lost due to the detri-
mental effect on neuronal cell survival caused by teratogenicity.
These results would support a role for pERK2 up-regulation in
increased memory [86,87], as well as the possibility of increased
protection against neuronal damage during bipolar disorder. The
Dictyostelium-based studies also identiﬁed other, non-teratogenic
VPA analogues (e.g. 2-methyl-2-pentenoic acid; Fig. 2D) that show
equal efﬁcacy to VPA, thus presenting potentially novel treat-
ments for bipolar disorder. In support of a cAMP/PKA dependent
mechanismof bipolar disorder drug action, lithium, carbamazepine
[88,89] and VPA [90–92] inhibit cAMP-based signalling in mam-
malian systems.
Future work regarding VPA-catalysed inhibition of the
cAMP/PKA/GSK3 signalling may provide mechanisms for the neu-
roprotective effects observed in treating bipolar disorder patients
[57,80].
7. Inositol and phosphoinositol attenuation and bipolar
disorder
Reduced inositol-dependent signalling was the ﬁrst proposed
mechanism for bipolar disorder treatments [54,93], primarily
based on a lithium-induced attenuation of inositol recycling
through inhibition of inositol monophophatase (IMPase) and inos-
itol polyphosphate 1-phosphatase (IPPase) [94]. Dictyostelium has
since proved an importantmodel for understanding the role of VPA
and lithium in regulating inositol signalling.
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Fig. 2. MAPK regulation by bipolar disorder treatments in the simple biomedical model Dictyostelium. In both Dictyostelium and mammalian systems, valproic acid (VPA)
and lithium (Li+) treatment leads to an increase in activated MAPK, illustrated here for the phosphorylation of the ERK2 (extracellular regulated kinase 2 [ERK2] to form
pERK2). (A) Regulation of pERK2 levels is complex, provided by a balance between kinase-dependent phosphorylation (catalysed byMEKK [mitogen-activated protein kinase
kinase kinse], and MEK [MAPK kinase kinase]) and by de-phosphorylation (catalysed by MKP [MAP kinase phosphatase] in the PKA [protein kinase A] and GSK3/A [glycogen
synthase kinase 3/A] signalling pathway). (B) Treatment of Dictyostelium cells with a single pulse of cyclic AMP (cAMP) gives rise to a transient increase in pERK2 detected
by using phosphorylation-speciﬁc antibodies. Pre-incubation of Dictyostelium cells with VPA (1mM, 60min) increases and elongates the pathway activation by an unknown
mechanism. (C) Research inDictyostelium enables the use of isogenic cell lines containing either ablated or over-expressed genes, providing valuable tools for pharmacological
research. For example, we can examine the role of GSKA (homologous to the human GSK3 proteins) in this effect by comparing pERK2 levels in wild-type cells and those
lacking GSKA, under control conditions (no added drug) or following Li+ (10mM, 60min, dark grey) OR VPA (1mM, 60min, light grey) treatment. GSKA ablation increases
pERK2 levels, suggesting that it functions as a negative regulator of this pathway, as does pharmacological inhibitionwith Li+. The lithium-dependent increase in pERK2 is also
signiﬁcantly reduced in the GSKA null, in agreement with a lithium/GSKA-dependent mechanism of action. In contrast, VPA causes a hypersensitive pERK2 increase in this
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PA (valpromide), enantiomeric compounds (R- and S-2-pentyl-4-pentynoic acid),
ctivation. **P<0.01, *P<0.05 compared to control.
Our previous work identiﬁed a common effect of VPA and
ithium in causing a reduction in InsP3 signalling in Dictyostelium
95] (Fig. 3). These studies identiﬁed prolyl oligopeptidase (PO), in a
EMI mutant screen for resistance to the effect of lithium in block-
ng development [93,95] (Fig. 1). The PO knockoutmutant was able
o overcome this block and hence form fruiting bodies, by elevat-
ng InsP3 levels. These studies also showed that VPA, lithium and
ne other bipolar disorder treatment (carbamazepine) induced a
ommonchange inmammalianneurons, and that this change could
e reversed by the addition of exogenous inositol or by inhibition
f PO activity (Fig. 3) [59,93]. This loss of PO activity gave rise to an
ncrease in the breakdown of InsP4, InsP5 and InsP6 to form InsP3.
O-dependent regulation of cellular InsP3 levels has since been
emonstrated in astroglioma and COS-7 kidney cell lines [96,97].
hus, PO ablation reverses the common effect of bipolar disorder
rugs. This was a novel discovery, since the role of PO was thought
o be entirely based upon the cleavage of small peptides containing
rolyl residues [98]. A link between PO enzyme activity and bipolar
isorder has also been reported in patients that exhibit increased
nzyme activity [21]. Furthermore, both Dictyostelium and mam-
alian systems have been used to identify a range of compounds
tructurally related to VPA that cause inositol depletion to show
hat this effect is not correlated with teratogenic activity [59,99].
The mechanism of lithium-dependent inositol phosphate regu-
ationhas recentlybeen further characterised inDictyostelium [100]
Fig. 3). King et al. [100] showed that chemotaxis provides a suitableh shows an unambiguous role of GSKA in the transient formation of pERK2. * P <0.05
re–activity relationship studies (SARs), where for example, the amide derivative of
ltered branch derivatives (2-ethyl-4-methylpentanoic acid) show altered pathway
model for examining the effects of lithium in Dictyostelium, since
it causes a strong reduction in cell speed. Ablation of PO activity
reduced sensitivity to this lithium effect, consistent with an InsP3-
dependent mechanism of lithium action. Ablation of the enzyme
multiple inositol polyphosphate phosphatase (MIPP), responsi-
ble for breakdown of InsP4–6, resulted in reduced InsP3 levels,
whereasMIPP over-expressing cell extracts had an enhanced activ-
ity compared to wild type controls. MIPP activity was necessary
for PO-inhibition dependent inositol phosphate regulation both in
chemotaxis and in theproduction of InsP3. These data clearly estab-
lish PO as the regulator of MIPP activity. However, surprisingly,
over-expression ofMIPP gave a lithiumhyper-sensitive phenotype.
The origin of lithium hyper-sensitivity in cells over-expressing
MIPP was found to be due to the elevated expression of a range
of genes related to inositol signalling [100]. These included IMPase
and IPPase—previously been described as cellular targets of lithium
[94], and inositol synthase 1 (INO1)—responsible for the de novo
synthesis of inositol. The increase in gene expression was also
observed following both genetic and pharmacological inhibition
of PO activity. However in all cases, this increased expression was
dependent upon thepresenceofMIPP activity andwas also induced
by over-expression of the kinases responsible for the production
of InsP4–6 from InsP3. Thus this work identiﬁed a gene regulatory
mechanism where the activation or over-expression of MIPP leads
to elevated expression of a range of inositol regulation genes inDic-
tyostelium. The results were then successfully translated to human
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Fig. 3. Inositol phosphate and phosphoinositide signalling regulation by bipolar disorder treatments in the simple biomedical model Dictyostelium. (A) Inositol signalling
initiates from the phospholipase C (PLC)-generated cleavage of membrane-bound phosphatidylinositol 4,5-biphosphate (PIP2) to produce diacylglycerol (DAG) and cytosolic
inositol 1,4,5-triphosphate (InsP3). Prolyl oligopeptidase (PO) negatively regulates multiple inositol polyphosphate phosphatase (MIPP) which in turn catalyses higher order
inositol (InsP4, InsP5, InsP6) breakdown to form InsP3. InsP3 is hydrolysed to InsP2 and further broken down by Inositol polyphosphate phosphatase (IPPase) and inositol
monophophatase (IMPase) to produce inositol. This is then incorporated into phosphoinositol signalling to form phosphatidylinositol (PI), phosphatidylinositol phosphate
(PIP) and then PIP2. DAG is recycled via phosphatidic acid (PA). Lithium plays a well-documented role in inhibiting IMPase and IPPase to reduce inositol-based signalling,
and VPA has been suggested to reduce de novo inositol biosynthesis through indirect inhibition of inositol synthase 1 (INO1), and the turnover of phosphoinositides (all
indicated in green). (B) The inositol head group of the family of phosphoinositide compounds act as a substrate for a range of kinases, providing a dynamic and complex
network of products and substrates. Addition of radio-labelled phosphate (red) to these kinase reactions gives rise to incorporation of radiolabel into deﬁned places on the
inositol ring (shown here for phosphatidylinositol 3-kinase (PI3K)). (C)Multiple substrates (shown here for PI3K) producemultiple products. Inositol ring (hexagon), P (black)
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Fhosphorylation site, P (Bold red) identiﬁed through Dictyostelium radio-labelling
eferences to color in this ﬁgure legend, the reader is referred to the web version of
ells (HEK293) to demonstrate that PO inhibition also up-regulates
everal IMPase genes and that this elevation is dependent on MIPP
ctivity. It is of interest that IMPasepolymorphismshavebeenasso-
iated with risk of bipolar disorder in family studies [101–103].
A newmechanism of action for bipolar disorder drugs has been
ecently proposed based uponwork inDictyostelium [104,105]. Ini-
ially, to characterise a VPA-dependent block in Dictyostelium cell
ovement, we investigated the role of phosphoinositide signalling
s a target forVPAaction [104]. VPA treatmentproduceda rapidand
trong reduction of phosphoinositide production. Further investi-
ation of this effect in Dictyostelium employed cells transformed
ith a PIP3 binding protein (PHcrac-GFP) enabling the time- and
ocation-dependent monitoring of PIP3 production. VPA produced
n acute (10min) reduction in PIP3 production, also shown by
educed PIP2 and PIP levels using in vivo radio-labelling exper-
ments (Fig. 3A and B, red). These effects were phenocopied by
harmacological inhibition of phosphatidylinositol 3-kinase (PI3K)
sing the inhibitor LY294002. Identiﬁcation of the mechanism
hat cause the inhibitory activity on phosphoinositide signalling is
ighly complex, since phosphorylation of the phosphatidylinositol
ead group can occur at three positions on the inositol ring (Fig. 3),
reating a variety of products including single phosphorylated
oieties (e.g. PI(3)P), as well as double and triple phosphorylated
roducts (e.g. PI(3,4)P2 and PI(3,4,5)P3). This data, for the ﬁrst time,
mplicated phosphoinositide signalling as a potential target for
ipolar disorder treatments. Considerable evidence suggests that
levated phosphoinositol signalling may be an underlying cause
f bipolar disorder since a variety of studies have identiﬁed this
ffect inbipolardisorderdrug-freepatients [106–108]aswell as the
ubsequent down-regulation of phosphoinositide levels following
ipolar disorder drug treatment [108,109].
Recent work on the effects of lithium on Dictyostelium has nowxtended the observation that bipolar disorder-treatment attenu-
tes phosphoinositide-mediated signalling [70]. The analysis of the
echanism leading to decreased cell speed following treatment
ndicated this effect is independently of both cAMP synthesis and
-actin polymerisation. However, the speed reduction was pheno-ver experiments, enzymes in blue (italics); ↓ decreased. (For interpretation of the
rticle.)
copied bypharmacological or genetic ablation of PI3K activity using
either LY294002 or a single Dictyostelium cell line lacking all ﬁve
PI3K genes [36] implicating phosphoinositide signalling as a target
for lithium treatment. In agreement with this, the phosphoryla-
tion of the protein kinase B (PkbA) homologue, whose membrane
translocation is dependent onbinding to thePHdomainof PIP3,was
also decreased following lithium treatment compared to untreated
cells. Furthermore, these effects also occurred in conjunction with
a decrease in the rate of PIP andPIP2 synthesis, althoughno changes
in steady-state concentrationof PIP2 levelsweredetected. Thismay
be due to a small rapidly turned over pool of PIP2 that is quickly
metabolised during chemostaxis providing a lithium sensitive tar-
get. Since the mechanism for inositol signalling attenuation by
lithium is known to function through the uncompetitive inhibition
of IMPase and IPPase [94], King et al. [70] over-expressed IMPase
to reverse the effects of lithium in PIP/PIP2 synthesis and PkbA
phosphorylation. The results were then successfully reproduced in
a human neutrophil cell line (HL60) where the translocation of a
PIP3-binding GFP construct to cell membranes (as a readout for
PIP3 production) was reduced following lithium treatment. Based
on these studies inDictyostelium investigatingbothVPAand lithium
mechanisms of action, we can now propose a new extension
of the current of inositol depletion hypothesis, whereby bipo-
lar disorder treatments give rise to attenuated phosphoinositide
signalling.
8. Conclusion/summary
Tohelp those diagnosedwith bipolar disorder, ongoing research
endeavours to identify the cell signalling changes that are tar-
getedby thepharmacological agents, valproic acid and lithium. This
approach overcomes the multitude of potential loci implicated in
the aetiology of the disorder, but instead focuses on understanding
the mechanism(s) leading to symptomatic control. It also enables
the identiﬁcation of new compounds that may be more efﬁcacious
or have reduced side effects in bipolar disorder treatment. Research
in this area has traditionally used rodents as model organisms,
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owever the increasing use of other simple model systems such
s Dictyostelium provides distinct advantages.
Investigation of cell signalling regulated by VPA and lithium
emonstrate that both Dictyostelium and the animal brain respond
y elevating pERK2 levels in the MAPK pathway. Analysis of this
ffect in Dictyostelium has proposed two mechanisms: VPA reg-
lates increased pERK2 levels through inhibition of cAMP/PKA
ignalling, whereas lithium inhibits GSK3/A, with both effects
eading to the reduced dephosphorylation of pERK2. The strong
tructural speciﬁcity of this effect in regards to VPA suggests novel
ompounds may be identiﬁed that show improved efﬁcacy for
APK regulation.
Another cell signalling effect of VPA and lithium inDictyostelium
s the reduction of inositol-dependent signalling. Recently studies
ave suggested that cellular inositol phosphate levels are
ontrolled by both inositol recycling and theMIPP-catalysed break-
own of higher-order inositol phosphate compounds (InsP4–6)
egulated by prolyl oligopeptidase activity. This work has also dis-
overed a transcriptional-based effect, whereby lithium treatment
ives rise to altered transcriptional regulation of inositol-signalling
elated genes. In addition Dictyostelium-based research has discov-
red a potential key pharmacological target of VPA and lithium
n attenuating phosphoinositol signalling, with both drugs caus-
ng an acute attenuation of phosphoinositol turnover. In the case
f lithium, it is likely that this effect is through inositol signalling
ttenuation, whereas themechanism controlled by VPA remains to
e determined. These discoveries open up a exciting ﬁeld of phos-
hoinositol research, with the promise of new therapies (based
round the structure of VPA) showing increased efﬁcacy in phos-
hoinositide regulation.
This review has summarised current research aimed at unrav-
lling the complex mechanisms of VPA and lithium in regulating
ell signalling, and the important role of Dictyostelium as a sim-
le biomedical model for this research. A better understanding of
hese cell signalling changes may ultimately identify the underly-
ng causes of bipolar disorder and will enable the development of
etter therapeutic treatments.
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